August 2019

Aurobindo Receives FDA Approval for Cinacalcet Hydrochloride Tablets, 30mg, 60mg, and 90mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for Cinacalcet Hydrochloride Tablets, 30mg, 60mg, and 90mg. Aurobindo’s Cinacalcet Hydrochloride Tablets are an AB-rated generic equivalent to the reference listed drug, Amgen Inc’s Sensipar. Cinacalcet Hydrochloride tablets are indicated for the […]

Aurobindo Receives FDA Approval for Cinacalcet Hydrochloride Tablets, 30mg, 60mg, and 90mg Read More »

Aurobindo Receives FDA Approval for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg. Aurobindo’s Fenofibric Acid Delayed-Release Capsules is an AB-rated generic equivalent to the reference listed drug, Abbvie Inc.’s TRILIPIX®. Fenofibric Acid Delayed-Release Capsules

Aurobindo Receives FDA Approval for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg Read More »